Peter Scanlon

Jun 30, 2023 | nature.com | Rebecca Jones |Irene M. Stratton |Peter Scanlon

Correction to: Eye https://doi.org/10.1038/s41433-023-02474-3, published online 14 March 2023The article “Disengagement and loss to follow-up in intravitreal injection clinics for neovascular age-related macular degeneration”, written by Rebecca Jones, Irene M. Stratton, Peter H. Scanlon and Sofia Theodoropoulou, was originally published electronically on the publisher’s internet portal on 14 March 2023 without open access.

Jun 8, 2023 | petescanlon-42994.medium.com | Peter Scanlon

By Peter Scanlon Think back to a time when you experienced a sense of connection that was empowering, liberating and fulfilling. You may express it was connected to certain life changes, challenges or triumphs seemingly aligned with groups, actions or a person. After a profound experience happens, "we" tend to find ourselves looking for the reason how or why, in an attempt to externally recreate a feeling in our life situation.

Mar 20, 2023 | nature.com | Faruque Ghanchi |Peter Scanlon |Hellen McGoey |Andrew Nolan

AbstractBackground/ ObjectivesDRAKO (NCT02850263) was a 24-month, prospective, observational, multi-centre cohort study that enrolled patients diagnosed with diabetic macular oedema (DMO) including central involvement. The study aimed to evaluate standard of care intravitreal aflibercept (IVT-AFL) treatment in the UK.

Mar 14, 2023 | nature.com | Rebecca Jones |Irene M. Stratton |Peter Scanlon

AbstractBackground/ObjectivesTimely assessment and treatment of patients with neovascular AMD (nAMD) are crucial to preservation of vision. Loss to follow up (LTFU) in these patients is a problem but this has not been systematically investigated. Subjects/MethodsA retrospective review of electronic medical records of patients with nAMD first treated with anti-VEGF therapy from 1st Jan 2014 to 31st Dec 2018, was conducted in January 2021.